Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin
Links shared publicly online about this topic.
- 1,191total visits
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chr
View full resource at news-medical.net
Tags: Cystic Fibrosis, Drug, Children's Health, FDA, Antibiotic, Cipro, Ciprobay, Pharmacokinetics
Most Recently Shared on May 5, 2010 at 1:05 pm By:
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin: Aradigm Corporation today announced it rece... http://bit.ly/cpSI0y
Advertisement
